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A bs tr ac t
Background
Preoperative cisplatin alone may be as effective as cisplatin plus doxorubicin in stan-
dard-risk hepatoblastoma (a tumor involving three or fewer sectors of the liver that 
is associated with an alpha-fetoprotein level of >100 ng per milliliter).
Methods
Children with standard-risk hepatoblastoma who were younger than 16 years of age 
were eligible for inclusion in the study. After they received one cycle of cisplatin (80 mg 
per square meter of body-surface area per 24 hours), we randomly assigned patients 
to receive cisplatin (every 14 days) or cisplatin plus doxorubicin administered in 
three preoperative cycles and two postoperative cycles. The primary outcome was 
the rate of complete resection, and the trial was powered to test the noninferiority 
of cisplatin alone (<10% difference in the rate of complete resection).
Results
Between June 1998 and December 2006, 126 patients were randomly assigned to re-
ceive cisplatin and 129 were randomly assigned to receive cisplatin plus doxorubicin. 
The rate of complete resection was 95% in the cisplatin-alone group and 93% in the 
cisplatin–doxorubicin group in the intention-to-treat analysis (difference, 1.4%; 95% 
confidence interval [CI], –4.1 to 7.0); these rates were 99% and 95%, respectively, in 
the per-protocol analysis. Three-year event-free survival and overall survival were, re-
spectively, 83% (95% CI, 77 to 90) and 95% (95% CI, 91 to 99) in the cisplatin group, 
and 85% (95% CI, 79 to 92) and 93% (95% CI, 88 to 98) in the cisplatin–doxorubicin 
group (median follow-up, 46 months). Acute grade 3 or 4 adverse events were more 
frequent with combination therapy (74.4% vs. 20.6%).
Conclusions
As compared with cisplatin plus doxorubicin, cisplatin monotherapy achieved sim-
ilar rates of complete resection and survival among children with standard-risk hepa-
toblastoma. Doxorubicin can be safely omitted from the treatment of standard-risk 
hepatoblastoma. (ClinicalTrials.gov number, NCT00003912.)
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Between 1990 and 1994, the Interna-tional Childhood Liver Tumour Strategy Group (SIOPEL) conducted its first coopera-
tive trial (SIOPEL 1), which set the standard of care 
for hepatoblastoma in most European countries.1 
With a 5-year event-free survival of 66% and an 
overall survival of 75%, the trial duplicated the 
results obtained by other investigators, particu-
larly in North America, during the same period.1-7 
SIOPEL 1 consisted of preoperative chemotherapy 
with a combination of cisplatin and doxorubicin 
followed by delayed surgery and further chemo-
therapy. Two pretreatment prognostic factors 
emerged from SIOPEL 1: intrahepatic tumor ex-
tension, as defined by a pretreatment tumor exten-
sion system (PRETEXT),8 and lung metastases.9 
On the basis of these findings, two pretreatment 
risk groups of hepatoblastoma were identified. 
Standard-risk hepatoblastoma is a tumor confined 
to the liver and involving not more than three he-
patic sectors. High-risk hepatoblastoma involves 
the entire liver; the portal vein, the right and left 
branches, or all three hepatic veins; or the inferior 
vena cava. High-risk hepatoblastoma may mani-
fest with intraabdominal disease, metastases, or 
both.9,10
At the time SIOPEL 1 was closed, the data from 
a trial comparing an anthracycline-free regimen 
(cisplatin plus fluorouracil plus vincristine) with 
cisplatin–doxorubicin started to become available.6 
They showed that the anthracycline-free regimen 
resulted in a 3-year overall survival of 71% and a 
disease-free survival of 63%, with no statistical 
differences between the two groups and no cardiac 
toxicity in the anthracycline-free regimen. These 
findings prompted us to ask whether doxorubicin 
could be safely omitted, at least from the treat-
ment of standard-risk hepatoblastoma, and wheth-
er cisplatin alone could be as effective as cisplatin 
plus doxorubicin. Consequently, we tested cisplatin 
alone in a pilot setting in 77 patients with stan-
dard-risk hepatoblastoma (SIOPEL 2) and found 
a response rate of 90% (95% confidence interval 
[CI], 80 to 96), a rate of complete resection of 97% 
(95% CI, 87 to 99), and a 3-year overall survival rate 
of 91% (95% CI, 84 to 98) and a progression-free 
survival rate of 89% (95% CI, 82 to 96).10 On 
the basis of these encouraging results, we con-
ducted the present prospective, randomized trial 
(SIOPEL 3) to compare the regimen of cisplatin 
plus doxorubicin with an experimental regimen of 
cisplatin alone in patients with standard-risk he-
patoblastoma. The primary end point was the rate 
of complete resection, and the secondary end 
points were 3-year overall survival and event-free 
survival and short-term toxicity.
Me thods 
Patients
The SIOPEL 3 standard-risk hepatoblastoma trial 
was an international cooperative, prospective, ran-
domized trial that was open for patient registra-
tion between June 1998 and December 2006. Chil-
dren younger than 16 years of age who had a 
previously untreated hepatoblastoma with stan-
dard-risk features, defined as a tumor entirely con-
fined to the liver and involving not more than 
three hepatic sectors,8-10 were eligible for the trial. 
During the trial, the protocol was amended to ex-
clude children presenting with hepatoblastoma 
and an alpha-fetoprotein level of less than 100 ng 
per milliliter, in view of mounting evidence of a 
poor outcome in these patients.11,12 All partici-
pating centers were required to obtain written 
approval from their local research ethics com-
mittees and written informed consent from the 
parents or legal guardians of the patients.
Pretreatment Evaluation of Tumor Extension
Tumor extension at diagnosis was assessed by ab-
dominal ultrasonography and computed tomog-
raphy (CT) with contrast medium, magnetic reso-
nance imaging (MRI) with contrast enhancement, 
or both. Lung metastases were identified by chest 
CT. Tumor extension was graded with the use of 
the PRETEXT system (on a scale of I to IV, with 
higher grades indicating tumor involvement in 
more sectors of the liver)8 (Fig. 1A in the Sup-
plementary Appendix, available with the full 
text of this article at NEJM.org). Patients with a 
PRETEXT I, II, or III hepatoblastoma and no evi-
dence of extrahepatic disease were eligible for 
the trial. In doubtful or borderline cases of risk 
assignment, participating centers could request a 
central review of radiologic images; replies were 
provided within 48 hours. Risk classification was 
confirmed in all 51 cases sent for central consul-
tation. Central review of the histologic slides de-
rived from tumor-biopsy specimens, resection, or 
both confirmed the histologic findings in all 175 
cases submitted.
Diagnosis and Study Design
Diagnostic biopsy was mandatory in children 
younger than 6 months of age because of the wide 
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differential diagnosis of hepatic masses and the 
possible confounding effect of an “elevated” serum 
alpha-fetoprotein level at this age and in children 
older than 3 years because of the risk of misdiag-
nosing hepatocellular carcinoma. In the case of 
unequivocal clinical findings (e.g., a solid hepatic 
mass and an elevated alpha-fetoprotein level), the 
decision to perform a diagnostic biopsy in chil-
dren between 6 months and 3 years of age was 
left to the individual center. If no biopsy was per-
formed, hepatoblastoma-compatible images and 
an elevated alpha-fetoprotein level were manda-
tory for randomization.
Within 7 days after the diagnosis of hepato-
blastoma, patients received a single cycle of cis-
platin while awaiting risk assignment (standard 
risk or high risk). We adopted this strategy to avoid 
delaying therapy. Within 15 days after receiving 
a definitive diagnosis, patients were randomly as-
signed to the cisplatin or cisplatin–doxorubicin 
group (Fig. 1B in the Supplementary Appendix). 
The initial cisplatin cycle (80 mg per square meter 
of body-surface area per 24 hours) was adminis-
tered in a continuous intravenous 24-hour infu-
sion. Subsequently, in the cisplatin group, cisplat-
in cycles (at the same dose) were administered 
at 14-day intervals. In the cisplatin–doxorubicin 
group, cisplatin–doxorubicin cycles were admin-
istered at 21-day intervals. Each cycle of cisplatin 
plus doxorubicin consisted of cisplatin on day 1, 
administered as described above, and doxorubicin 
at a dose of 30 mg per square meter of body-
surface area per day, administered as a continu-
ous intravenous 24-hour infusion on days 2 and 
3. Four cycles of cisplatin (in the cisplatin group) 
or one cycle of cisplatin and three cycles of cis-
platin plus doxorubicin (in the cisplatin–doxoru-
bicin group) had to be administered before delayed 
surgery (preoperative chemotherapy).
The tumor response was assessed after four 
cycles of cisplatin (in the cisplatin group) or after 
one cycle of cisplatin and three cycles of cisplat-
in plus doxorubicin (in the cisplatin–doxorubicin 
group). If the tumor was considered to be re-
sectable, radical surgery was attempted (delayed 
surgery). Patients with complete resection were 
scheduled to receive two more cycles of cisplatin 
or cisplatin plus doxorubicin. If, after the first 
four cycles of chemotherapy, the tumor had re-
sponded somewhat but was still considered to be 
unresectable, two more cycles were to be given 
before surgery, but none afterward. Thus, each 
patient was scheduled to receive a maximum of 
six cycles of cisplatin or one cycle of cisplatin 
and five cycles of cisplatin plus doxorubicin. The 
chemotherapy regimen was purposely designed 
to be flexible in order to take all possible clinical 
situations into account. We evaluated the tumor 
response on the basis of abdominal ultrasound, 
CT, or MRI findings using the same criteria we 
used in previous SIOPEL studies.1,10 Detailed guide-
lines for adjustment of the drug dosage to the 
patient’s weight (if <10 kg) and in relationship to 
hematologic and organ toxicity were provided in 
the study protocol. The use of granulocyte colony-
stimulating factor was not recommended. A sys-
tem for monitoring serious adverse events was 
implemented.
Randomization Procedures 
The United Kingdom Children’s Cancer Study 
Group Data Centre was the trial office. Partici-
pating institutions sent a prerandomization form 
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Figure 1. Enrollment and Randomization.
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to the trial office to request randomization. Sub-
sequently, eligible patients were randomly assigned 
to one of the two treatment groups by the mini-
mization method, and the results were communi-
cated to the participating center.
Outcome Definition 
Complete resection was defined as resection of 
all tumor sites on the basis of surgical findings and 
on postsurgical images. Event-free survival was de-
fined as the interval between diagnosis and dis-
ease progression, relapse, or death, whichever oc-
curred first, and overall survival was defined as 
the interval between diagnosis and death from any 
cause or last contact. Patients who were alive at the 
last contact were excluded on that date. Severe 
acute toxicity was defined as the rate of grade 3 
or 4 infection, stomatitis, febrile neutropenia, or all 
of these events, according to the National Cancer 
Institute Common Toxicity Criteria.
Statistical Analysis
The study design was based on a test of noninfe-
riority of cisplatin as compared with cisplatin plus 
doxorubicin for the primary end point (the rate of 
complete resection after preoperative chemother-
apy). The protocol stated that cisplatin would be 
considered to be noninferior to cisplatin plus dox-
orubicin if the rate of complete resection was not 
decreased by more than 10 percentage points from 
the 90 percentage points expected with cisplatin 
plus doxorubicin. This 10% margin was used for 
interim monitoring. Given the rarity of this tumor 
and the expected yearly recruitment of 30 to 35 
patients, it was recognized that a tighter noninfe-
riority margin could not be planned. A two-sided 
95% confidence interval was chosen for the final 
evaluation of the primary end point. The sample 
size was estimated at 250 patients to test nonin-
feriority with a one-sided, two-sample difference-
in-proportions test for the comparison of the rates 
of complete resection, with an error rate fixed at 
5% for incorrectly accepting noninferiority and a 
power of 80%. This sample size yields a two-sided 
95% confidence interval with 60% power to exclude 
a 10% difference. To avoid a potential bias intro-
duced by nonprotocol chemotherapy administered 
before surgery, a per-protocol analysis was per-
formed in addition to the intention-to-treat anal-
ysis.13 Toxicity rates were compared by means of 
odds ratios and 95% confidence intervals. Kaplan–
Meier survival estimates were compared with the 
use of the log-rank test.14 SAS software, version 
9.1, was used for all evaluations.
Interim results were evaluated yearly and were 
submitted in an unblinded fashion to an indepen-
dent data and safety monitoring committee con-
sisting of three pediatric oncologists and one 
statistician who were not involved in the trial. 
The independent data and safety monitoring 
committee endorsed continuation of the trial at all 
interim evaluations. A group-sequential approach 
involving a Lan–DeMets alpha-spending function 
with O’Brien–Fleming–type boundaries was used 
to calculate adjusted significance levels for five 
comparisons of the primary end point.
The SIOPEL 3 trial committee independently 
designed the study under the chairmanship of one 
of the authors. The United Kingdom Children’s 
Cancer Study Group Data Centre collected the 
data. The study biostatistician performed the 
analyses. Finally, the trial committee, led by one of 
the authors, wrote the first and the final drafts 
of the manuscript.
R esult s
Patients 
Between June 1998 and December 2006, a total 
of 92 institutions from 24 countries randomly as-
Table 1. Baseline Characteristics of the Study Participants, According to 
Treatment Group.
Variable
Cisplatin
(N = 126)
Cisplatin plus 
Doxorubicin 
(N = 129)
Total
(N = 255)
Sex (no.)
Female 49 51 100
Male 77 78 155
Age (mo)
Median 12 15 13.5
Range 0–134 0.2–133.0 0–134
PRETEXT stage (no.)
I 9 9 18
II 64 69 133
III 53 51 104
Alpha­fetoprotein (no.)*
<100 ng/ml 0 1 1
100–1,000,000 ng/ml 116 114 230
>1,000,000 ng/ml 9 13 22
* Alpha­fetoprotein levels in two patients were not known.
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signed 267 patients (Fig. 1). Of these patients, 
five patients were excluded because the diagnosis 
was revised locally soon after the initial diagno-
sis (nodular hyperplasia in one patient, hamar-
toma in one patient, and a benign lesion not 
otherwise specified in three patients). Seven pa-
tients were excluded because they lacked proper 
documentation. The modified intention-to-treat 
sample consisted of the 255 patients considered 
to be eligible and evaluable (126 patients in the 
cisplatin group and 129 in the cisplatin–doxoru-
bicin group). The database was locked on August 
20, 2008. The characteristics of the study popula-
tion are summarized in Table 1. The diagnosis 
was based on biopsy findings in 172 patients and 
on unequivocal clinical findings, as per-proto-
col guidelines, in the remaining 83. The diagno-
sis was confirmed at surgery in all patients who 
received a diagnosis based on unequivocal clini-
cal findings.
Treatment Outcomes
The response rate was 90% in the cisplatin group 
and 95% in the cisplatin–doxorubicin group (Ta-
ble 2), and the rate of complete resection was 
95% and 93%, respectively. The intention-to-treat 
analysis showed the noninferiority of cisplatin by 
a margin of 10%: the rate of complete resection 
in the cisplatin group minus the rate of complete 
resection in the cisplatin–doxorubicin group was 
1.4% (95% CI, –4.1 to 7.0). We also carried out a 
per-protocol analysis after the exclusion of 20 pa-
tients (16 randomly assigned to cisplatin and 4 ran-
domly assigned to cisplatin plus doxorubicin) be-
cause of presurgical therapy that was not in the 
protocol or categorization as high risk (Fig. 1). 
The rates of complete resection were 99% with 
cisplatin and 95% with cisplatin plus doxorubicin, 
with a difference of 3.9% (95% CI, –0.3 to 8.1). 
The 3-year overall survival rates were 95% with 
cisplatin versus 93% with cisplatin plus doxoru-
bicin, and the event-free survival rates were 83% 
with cisplatin versus 85% with cisplatin plus dox-
orubicin (median follow-up time, 46 months) (Ta-
ble 2 and Fig. 2).
Disease Progression, relapse, and Death
A total of 34 randomly assigned patients had a 
documented relapse or disease progression: 19 in 
the cisplatin group (15%) and 15 in the cisplatin–
doxorubicin group (12%) (Table 2). Seven patients 
in the cisplatin group and eight in the cisplatin–
doxorubicin group died. One death in the cisplat-
in group and two deaths in the cisplatin–doxoru-
bicin group were due to surgical complications. 
Neither the risk of relapse nor the risk of death 
differed between the two groups. Of the 19 patients 
with relapse or disease progression in the cisplat-
in group, 13 had local progression and 6 had me-
tastases. Of the latter six patients, five were alive 
with no evidence of disease (duration of follow-
up, 18 months to 7.5 years; median, 5.5 years). Of 
the 15 patients treated with cisplatin plus doxo-
rubicin who had a relapse, 9 had local progression 
and 6 had metastases. At the last observation, four 
of these six patients were alive without evidence 
of disease (duration of follow-up, 4 months to 
6 years; median, 16 months).
Table 2. Efficacy Measures, According to Treatment Group.
Outcome Cisplatin (N = 126)
Cisplatin plus 
Doxorubicin (N = 129)
Hazard Ratio 
(95% CI)
P  
Value
Partial response — no. (% [95% CI]) 114 (90.5 [84 to 95]) 122 (94.6 [89 to 98])
Stable disease — no. (%) 5 (4.0) 3 (2.3)
Progressive disease — no. (%) 6 (4.8) 1 (0.8)
Not documented — no. (%) 1 (0.8) 3 (2.3)
Complete resection — no. (% [95% CI])* 120 (95.2 [90 to 98]) 121 (93.8 [88 to 97])
Relapse or disease progression — no. (%) 19 (15.1) 15 (11.6) 0.81 (0.42 to 1.54) 0.52
Death — no. (%) 7 (5.6) 8 (6.2) 1.14 (0.42 to 3.2) 0.79
Overall survival at 3 yr — % (95% CI) 95 (91 to 99) 93 (88 to 89)
Event­free survival at 3 yr — % (95% CI) 83 (77 to 90) 85 (79 to 92)
* The difference in the complete resection rate between the cisplatin group and the cisplatin–doxorubicin group was 1.4 
(95% CI, –4.1 to 7.0).
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Adverse Events
The median number of cycles of preoperative che-
motherapy in both groups was four as per proto-
col (three to six cycles in the cisplatin group 
and one to six cycles in the cisplatin–doxorubicin 
group), and the median number of postoperative 
cycles was two in both groups, as planned (zero 
to three cycles in the cisplatin group and zero to 
four cycles in the cisplatin–doxorubicin group). 
Four patients received seven cycles, and one pa-
tient received eight cycles. Table 3 summarizes the 
toxic events in each treatment group. Hearing loss 
was evaluated according to the criteria of Brock 
et al.15 (on the basis of institutional reporting). 
Acute grade 3 or 4 adverse events were more fre-
quent in the cisplatin–doxorubicin group than in 
the cisplatin-only group (74.4% vs. 20.6%). At least 
one hearing test was obtained during follow-up in 
168 patients. Some hearing loss was documented 
in 32% of the patients tested (53 of 168). No dif-
ferences in ototoxicity or nephrotoxicity were de-
tected between the two groups.
Among the 80 patients in the cisplatin–doxo-
rubicin group with at least one evaluation during 
follow-up, 1 had a left ventricular shortening frac-
tion of less than 28% and 4 others had values 
between 29% and 30%. Of the 44 patients in the 
cisplatin group for whom a shortening fraction 
value was available during follow-up, 1 had a 
shortening fraction of less than 28% (at diagno-
sis it was 35%), but he received two cycles of doxo-
rubicin postoperatively; 4 patients had shortening 
fraction values between 29% and 30%. Given these 
small numbers, a longer follow-up is needed to 
assess impairment of cardiac function accurately.
Discussion
The SIOPEL 3 trial demonstrates the noninferior-
ity of the rate of complete resection observed in a 
cohort of patients with standard-risk hepatoblas-
toma treated with cisplatin alone as compared 
with cisplatin–doxorubicin. The rate of complete 
resection was chosen as the primary study end 
point, first because it allowed us to obtain mean-
ingful data regarding the treatment of a very rare 
tumor in a reasonable time frame and second, and 
more importantly, because complete resection is 
the universally accepted, single most important 
prognostic factor for long-term overall survival 
and event-free survival in childhood hepatoblas-
toma.1-7,9-11 Strict noninferiority in the sense of a 
clinically acceptable marginal difference could not 
be statistically proved because of the limited num-
ber of patients. Nevertheless, we were able to rule 
out, with 97.5% probability, a reduction of more 
than 4.1% in the rate of complete resection in the 
cisplatin group in the intention-to-treat analysis. 
In addition, the similar rates of 3-year overall sur-
vival (95% and 93%) and event-free survival (83% 
and 85%) in the cisplatin and cisplatin–doxorubi-
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Figure 2. Outcomes in Patients with Standard-Risk  
Hepatoblastoma Who Received Cisplatin Alone  
versus Cisplatin plus Doxorubicin.
Panel A shows Kaplan –Meier curves for event­free 
 survival, and Panel B shows Kaplan –Meier curves for 
overall survival. 
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cin groups, respectively, provide support for the 
noninferiority of cisplatin as compared with cis-
platin–doxorubicin and bode well for the defini-
tive cure of children with standard-risk hepato-
blastoma.
We cannot compare our rate of complete re-
section and data on overall survival and event-
free survival with those of other trials because of 
differences in risk stratification among studies. 
The results of SIOPEL 3 are very encouraging. It 
has long been known that surgery has an excel-
lent success rate in children with hepatoblastoma 
and that hepatoblastomas are very sensitive to 
cisplatin. However, the SIOPEL 3 trial shows that 
a selected group of patients with hepatoblastoma 
can be cured with a strategy consisting of cisplat-
in monotherapy administered preoperatively and 
postoperatively.
Table 3. Adverse Events, According to Treatment Group.
Variable Cycles Patients
Cisplatin 
(N = 727)
Cisplatin plus 
Doxorubicin 
(N = 746)
Cisplatin 
(N = 126)
Cisplatin plus 
Doxorubicin 
(N = 129)
Odds Ratio 
(95% CI)
number (%)
Acute toxic effects
Grade 3 or 4 febrile neutropenia 12 (1.7) 158 (21.2) 7 (5.6) 82 (63.6) 9.1 (4.4–18.7)
Grade 3 or 4 infection 32 (4.4) 92 (12.3) 24 (19.0) 58 (45.0) 2.0 (1.4–2.9)
Grade 3 or 4 mucositis 2 (0.3) 31 (4.2) 2 (1.6) 20 (15.5) 5.9 (1.6–22.1)
Severe toxic effects (any of above) 40 (5.5) 204 (27.3) 26 (20.6) 96 (74.4) 3.5 (2.5–5.0)
Cycles administered at reduced dose
Cisplatin 24 (3.3) 34 (4.6)
Doxorubicin 44 (5.9)
Cycle delays 54 (7.4)* 145 (19.4)† 38 (30.2) 79 (61.2)
Toxic effects during follow-up
Ototoxicity according to Brock et al.15 — no./ 
total no. (%)
Grade 0 62/89 (69.6) 53/79 (67.1)
Grade 1 9/89 (10.1) 11/79 (13.9)
Grade 2 13/89 (14.6) 8/79 (10.1)
Grade 3 2/89 (2.2) 5/79 (6.3)
Grade 4 3/89 (3.4) 2/79 (2.5)
Glomerular filtration rate — no./total no. (%)
<60 ml/min/1.73 m2 3/80 (3.7) 3/71 (4.2)
60–79 ml/min/1.73 m2 19/80 (23.7) 5/71 (7.0)
≥80 ml/min/1.73 m2 58/80 (72.5) 63/71 (88.7)
Subnormal magnesium level — no./total no. (%) 22/99 (22.2) 18/96 (18.7)
Left ventricular shortening fraction — no./total 
no. (%)
≤28% 1/44 (2.3)‡ 1/80 (1.2)
29 to <30% 4/44 (9.1) 4/80 (5.0)
30% 39/44 (88.6) 75/80 (93.7)
* The median number of days in the cycle was 6 (range, 2 to 29).
† The median number of days in the cycle was 7 (range, 1 to 39).
‡ This patient received doxorubicin on an off­protocol basis.
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As predicted, cisplatin alone had significantly 
less hematologic toxicity than cisplatin plus doxo-
rubicin and was equally as ototoxic and neph-
rotoxic. The every-14-day schedule of cisplatin ad-
ministration in the cisplatin-alone group was 
feasible and accompanied by minimal hematologic 
toxicity and acceptable ototoxicity and nephro-
toxicity. Four patients in the cisplatin group had 
a moderate reduction of the shortening fraction. 
A longer follow-up is needed to understand the 
real significance of this finding.
Therapeutic strategies consisting of primary 
surgery and three to four cycles of adjuvant mul-
tiagent, cisplatin-based chemotherapy have also 
resulted in excellent outcomes in patients with 
limited-extension hepatoblastoma.3,6 In Intergroup 
Trial 0098, patients with hepatoblastoma who un-
derwent a complete microscopic and macroscopic 
surgical excision (both stage I unfavorable histo-
logic features and stage II) had a 5-year event-free 
survival of 91% and 100%, respectively, with four 
cycles of either cisplatin–doxorubicin or cisplatin 
plus fluorouracil plus vincristine.6 Even more strik-
ing, the few hepatoblastomas with pure fetal his-
tologic features and low mitotic rate seem to be 
curable with surgery alone.16 However, emerging 
evidence indicates that small-cell undifferentiated 
histologic features may have a negative impact on 
survival, regardless of tumor extension.16,17 There-
fore, the conceptualization of future clinical trials 
should take into account the data from all avail-
able trials to refine the appropriate therapy for 
subgroups of patients with limited-extension he-
patoblastoma and to properly balance efficacy and 
long-term toxicity.
In summary, the SIOPEL 3 standard-risk he-
patoblastoma trial demonstrates that a simple, 
moderately toxic, easy-to-administer monotherapy 
regimen with cisplatin is not inferior to the com-
bination of cisplatin and doxorubicin in patients 
with accurately staged standard-risk hepatoblas-
toma in terms of the rate of complete resection, 
but it is, as predicted, less toxic.
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